Home › Compare › PNADF vs ABBV
PNADF yields 6.15% · ABBV yields 3.06%● Live data
📍 PNADF pulled ahead of the other in Year 1
Combined, PNADF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PNADF + ABBV for your $10,000?
PETRONAS Dagangan Berhad, together with its subsidiaries, engages in retailing and marketing of downstream petroleum products primarily in Malaysia. It operates through Retail, Commercial, and Others segments. The company offers petroleum and non-fuel products and services; and markets diesel, jet A-1, fuel oil, bitumen, gasoline, mogas, methanol, LNG, smartpay cards, kerosene, petroleum coke and Sulphur, and others to various industries and market segments, including agriculture, aviation, mining and quarrying, bunker, construction, manufacturing, and services. It also offers liquefied natural gas (LPG) for household, commercial, and industrial segments; and lubricant products, including passenger car motor oils, motorcycle oils, commercial vehicle lubricants, and industrial and marine lubricants under PETRONAS Syntium, PETRONAS Sprinta, and PETRONAS Urania brands for consumers and commercial customers. The company sells its products through approximately 1,000 PETRONAS stations and 800 Kedai Mesra convenience stores. In addition, it offers aviation fueling, courier, technical consultancy, and payment services; operates as a general carrier and forwarding agent; manages and operates Mesra C-stores, and food and beverage stores. The company was founded in 1981 and is headquartered in Kuala Lumpur, Malaysia. PETRONAS Dagangan Berhad is a subsidiary of Petroliam Nasional Berhad.
Full PNADF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.